SCHEMBL2473282

SCHEMBL2473282

COc1ccccc1C(=O)NC(C1(c2ccccc2)CCNCC1)S(=O)(=O)N(F)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KCNA3 P22001 8/20 0.38
SLC6A9 P48067 1/20 0.37
NPC1 O15118 3/20 0.36
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
CCR8 P51685 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
ITGB7 P26010 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471910 0.95 ALDH1A1 (0.41) GAARAB9AALDH1A1KMT2AMEN1
SCHEMBL2469428 0.86 ALDH1A1 (0.44) RAB9AALDH1A1KMT2AMEN1HPGD
SCHEMBL2468331 0.86 ALDH1A1 (0.44) RAB9AALDH1A1KMT2AMEN1HPGD
SCHEMBL2473080 0.86 ALDH1A1 (0.42) ALDH1A1KMT2AMEN1HPGDKCNA3
SCHEMBL2467688 0.85 KDM4E (0.44) GAASMN1; SMN2RAB9AALDH1A1KMT2A
SCHEMBL2467306 0.84 ALDH1A1 (0.45) RAB9AALDH1A1KMT2AMEN1HPGD
SCHEMBL2471276 0.84 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1HPGDKCNA3
SCHEMBL2472448 0.84 GAA (0.41) GAASMN1; SMN2RAB9AALDH1A1KMT2A
SCHEMBL2468321 0.84 ALDH1A1 (0.44) RAB9AALDH1A1KMT2AMEN1HPGD
SCHEMBL2701694 0.83 SMN1; SMN2 (0.40) GAASMN1; SMN2RAB9AALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 GAA 3999/4885SMN1; SMN2 4032/4885RAB9A 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.